Overview

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus MMF in Participants With Childhood Onset Idiopathic Nephrotic Syndrome

Status:
Not yet recruiting

Trial end date:
2026-08-15

Target enrollment:

Participant gender:

Summary

This open-label, randomized multicenter study is to assess the efficacy, safety, and pharmacokinetics (PK)/pharmacodynamics (PD) of obinutuzumab compared with mycophenolate mofetil (MMF) in children and young adults (aged >= 2-25 years) with frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS).

Phase:

Phase 3

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Acetaminophen
Diphenhydramine
Methylprednisolone
Obinutuzumab
Prednisone
Promethazine